- The gastrointestinal (GI) tolerability of ASC47 in combination with semaglutide was significantly better than placebo in combination with semaglutide (semaglutide monotherapy). The incidence of vomiting was 6.7% in ASC47 in combination with semaglutide group compared to 57.1% in the semaglutide monotherapy group. - Ultra-long-acting subcutaneous (SQ) depot formulation of ASC47...
DOVER, Del., July 17, 2025 /PRNewswire/ -- B2B Rocket, a fast-scaling AI sales automation company built to help small and mid-sized businesses grow faster,...